Jefferies Financial Group set a €43.00 ($50.00) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Wednesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other research analysts have also recently issued reports on FRE. Barclays set a €52.00 ($60.47) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Thursday, July 18th. Independent Research set a €51.00 ($59.30) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, August 2nd. Morgan Stanley set a €50.00 ($58.14) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Wednesday, May 22nd. Warburg Research set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, July 26th. Finally, HSBC set a €52.00 ($60.47) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, August 30th. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of €57.96 ($67.39).

Shares of Fresenius SE & Co KGaA stock opened at €44.35 ($51.56) on Wednesday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02). The company’s 50 day moving average price is €44.06 and its 200-day moving average price is €47.25.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.